Targets › ALAD
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Dec 2026.
Catalyzes an early step in the biosynthesis of tetrapyrroles. Binds two molecules of 5-aminolevulinate per subunit, each at a distinct site, and catalyzes their condensation to form porphobilinogen. (UniProt, P13716)
Open in Phaseline: the race on ALAD, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| michal roll | 5-AMINOLEVULINIC ACID (5-ALA) Prodrug metabolized to protoporphyrin IX for photodynamic therapy | ALAD | Phase 2 | The Aim of the Study is to Evaluate the Efficacy of Photodynamic Therapy as an | Dec 2026 |
The Aim of the Study is to Evaluate the Efficacy of Photodynamic Therapy as an (1)
small molecule (1)
michal roll (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.